Masimo Co. (NASDAQ:MASI) Receives Average Recommendation of "Moderate Buy" from Brokerages

Masimo Co. (NASDAQ:MASI - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seven brokerages that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $179.67.

Several research firms have issued reports on MASI. Raymond James boosted their price objective on shares of Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a research report on Friday, December 27th. BTIG Research boosted their price target on Masimo from $166.00 to $170.00 and gave the company a "buy" rating in a report on Monday, October 14th. Piper Sandler raised their price objective on Masimo from $180.00 to $210.00 and gave the stock an "overweight" rating in a report on Wednesday, December 18th. Stifel Nicolaus reiterated a "buy" rating and issued a $190.00 target price (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Finally, Wells Fargo & Company increased their price target on Masimo from $171.00 to $193.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 11th.

Hedge Funds Weigh In On Masimo

Several institutional investors and hedge funds have recently added to or reduced their stakes in MASI. NBC Securities Inc. grew its holdings in Masimo by 47.1% in the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider's stock worth $30,000 after purchasing an additional 73 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in Masimo by 133.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider's stock worth $44,000 after buying an additional 200 shares during the last quarter. HHM Wealth Advisors LLC increased its position in Masimo by 25.0% during the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider's stock valued at $79,000 after buying an additional 125 shares in the last quarter. Headlands Technologies LLC purchased a new stake in Masimo in the second quarter valued at about $109,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in Masimo in the third quarter worth about $118,000. Hedge funds and other institutional investors own 85.96% of the company's stock.

Masimo Trading Down 2.0 %

Shares of Masimo stock traded down $3.29 during trading on Wednesday, hitting $165.30. The stock had a trading volume of 336,119 shares, compared to its average volume of 656,805. The stock has a market cap of $8.85 billion, a PE ratio of 114.00 and a beta of 1.01. Masimo has a 12 month low of $101.61 and a 12 month high of $180.97. The firm's fifty day simple moving average is $164.35 and its 200-day simple moving average is $136.98. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11.

Masimo (NASDAQ:MASI - Get Free Report) last announced its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. During the same quarter in the previous year, the business earned $0.63 earnings per share. The company's revenue for the quarter was up 5.4% compared to the same quarter last year. As a group, sell-side analysts expect that Masimo will post 4.03 EPS for the current fiscal year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.